autophagy related 4B cysteine peptidaseGenealiases: APG4B · AUTL1 · HsAPG4B
Q-omics provides the consensus-scored ATG4B profile across patient tissues and cancer cell-line models. ATG4B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ATG4B is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ATG4B RNA expression shows 19,863 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where ATG4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATG4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATG4B survival associations across molecular data types. ATG4B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATG4B RNA expression–survival associations across cancer types. High ATG4B expression shows unfavorable associations in ACC, KIRC, LIHC and LGG, but favorable associations in HNSC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ATG4B RNA expression.
This table summarizes ATG4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ATG4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATG4B shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LIHC, STAD and HNSC. The COAD box plot shows higher ATG4B RNA expression in tumor versus normal tissue (log2 FC = +0.743, t-test p < 0.001).
This table shows molecular features associated with ATG4B in patient tissues and cancer cell lines. In patient samples, ATG4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATG4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
